{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:00:35Z","timestamp":1795042835164,"version":"4.10.2"},"reference-count":41,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Non-factor therapies are changing the treatment paradigm in hemophilia A, which was previously dominated by replacement- therapy using factor VIII (FVIII) concentrates. However, the FVIII equivalence of these new therapies has remained unclear, since in vitro assays generate variable responses. Here we used four different in vivo bleeding models to compare FVIII to emicizumab and to a sequence-identical analog of the tissue factor pathway inhibitor-targeting antibody marstacimab (SIA-marstacimab). The severity of these models was variable, each requiring different doses of FVIII to reduce blood loss to levels of wild-type mice. For example, a dose of 2.5 IU\/kg FVIII was needed for full correction in the tail vein transection (TVT) model, whereas 25 IU\/kg was needed in the saphenous vein puncture (SVP) model. Intermediate doses were required in the tail artery transection (TAT) model (5 IU\/kg) and tail clip model (7.5 IU\/kg). Importantly, FVIII treatment produced stable clots, without spontaneous rebleeds being observed. Both emicizumab and SIA-marstacimab (used at therapeutic doses of 55 \u03bcg\/mL and 16 \u03bcg\/mL, respectively) displayed a variable, model-dependent FVIII equivalence. For example, emicizumab proved equivalent to 5 IU\/kg FVIII in the tail clip model, and to 10 IU\/kg in the SVP model. Strikingly, both emicizumab and SIA-marstacimab treatment resulted in spontaneous rebleeds in the TVT, TAT and tail clip models, further distinguishing them from FVIII treatment. Our data suggest that there is unlikely to be a single FVIII equivalence for emicizumab, SIA-marstacimab, and similar molecules, because their activity is dependent on local conditions and severity of the injury.<\/jats:p>","DOI":"10.3324\/haematol.2024.286982","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T03:56:10Z","timestamp":1743652570000},"page":"2064-2075","source":"Crossref","is-referenced-by-count":7,"title":["Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice"],"prefix":"10.3324","volume":"110","author":[{"given":"Thibaud","family":"Sefiane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"McCluskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortense","family":"Maynadi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Peyron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tovo","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Brochier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Saller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem","family":"Khamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile V.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier D.","family":"Christophe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Lenting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Muczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Casari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"78671","doi-asserted-by":"crossref","unstructured":"Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019; 133(5):389-398.","DOI":"10.1182\/blood-2018-08-872291"},{"key":"78672","doi-asserted-by":"crossref","unstructured":"Kitazawa T, Igawa T, Sampei Z. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012; 18(10):1570-1574.","DOI":"10.1038\/nm.2942"},{"key":"78673","doi-asserted-by":"crossref","unstructured":"Oldenburg J, Mahlangu JN, Kim B. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017; 377(9):809-818.","DOI":"10.1056\/NEJMoa1703068"},{"key":"78674","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I. Emicizumab prophylaxis in patients who have hemophilia A without Inhibitors. N Engl J Med. 2018; 379(9):811-822.","DOI":"10.1056\/NEJMoa1803550"},{"key":"78675","doi-asserted-by":"crossref","unstructured":"Callaghan MU, Negrier C, Paz-Priel I. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021; 137(16):2231-2242.","DOI":"10.1182\/blood.2020009217"},{"key":"78676","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022; 28(Suppl 4):103-110.","DOI":"10.1111\/hae.14524"},{"key":"78677","doi-asserted-by":"crossref","unstructured":"Matsushita T, Shapiro A, Abraham A. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023; 389(9):783-794.","DOI":"10.1056\/NEJMoa2216455"},{"key":"78678","doi-asserted-by":"crossref","unstructured":"Mahlangu J, Luis Lamas J, Cristobal Morales J. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results. Br J Haematol. 2023; 200(2):240-248.","DOI":"10.1111\/bjh.18495"},{"key":"78679","doi-asserted-by":"crossref","unstructured":"Mahlangu JN, Lamas JL, Morales JC. A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023; 200(2):229-239.","DOI":"10.1111\/bjh.18420"},{"key":"78680","doi-asserted-by":"crossref","unstructured":"Lenting PJ. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv. 2020; 4(9):2111-2118.","DOI":"10.1182\/bloodadvances.2019000849"},{"key":"78681","doi-asserted-by":"crossref","unstructured":"Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood. 2017; 130(23):2463-2468.","DOI":"10.1182\/blood-2017-08-801662"},{"key":"78682","doi-asserted-by":"crossref","unstructured":"Leksa NC, Aleman MM, Goodman AG, Rabinovich D, Peters R, Salas J. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence. J Thromb Haemost. 2019; 17(7):1044-1052.","DOI":"10.1111\/jth.14430"},{"key":"78683","doi-asserted-by":"crossref","unstructured":"Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995; 10(1):119-121.","DOI":"10.1038\/ng0595-119"},{"key":"78684","unstructured":"Apgar JR, Benard S, Carven GJ. Tissue factor pathway inhibitor antibodies and uses thereof. USPTO; 2017, WO201729583A2. 2024. Publisher Full Text|"},{"key":"78685","doi-asserted-by":"crossref","unstructured":"Johansen PB, Tranholm M, Haaning J, Knudsen T. Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules. Haemophilia. 2016; 22(4):625-631.","DOI":"10.1111\/hae.12907"},{"key":"78686","doi-asserted-by":"crossref","unstructured":"Pastoft AE, Lykkesfeldt J, Ezban M, Tranholm M, Whinna HC, Lauritzen B. A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate\u00ae). Haemophilia. 2012; 18(5):782-788.","DOI":"10.1111\/j.1365-2516.2012.02780.x"},{"key":"78687","doi-asserted-by":"crossref","unstructured":"Pittman DD, Rakhe S, Bowley SR, Jasuja R, Barakat A, Murphy JE. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022; 6(2):e12679.","DOI":"10.1002\/rth2.12679"},{"key":"78688","doi-asserted-by":"crossref","unstructured":"Ferriere S, Peyron I, Christophe OD. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020; 136(6):740-748.","DOI":"10.1182\/blood.2019004334"},{"key":"78689","doi-asserted-by":"crossref","unstructured":"Berntorp E, Astermark J, Bjorkman S. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia. 2003; 9(Suppl 1):1-4.","DOI":"10.1046\/j.1365-2516.9.s1.17.x"},{"key":"78690","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26(Suppl 6):1-158.","DOI":"10.1111\/hae.14046"},{"key":"78691","doi-asserted-by":"crossref","unstructured":"Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A. The predictive value of factor VIII\/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. J Thromb Haemost. 2018; 16(10):2106-2110.","DOI":"10.1111\/jth.14257"},{"key":"78692","doi-asserted-by":"crossref","unstructured":"Iorio A, Iserman E, Blanchette V. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia. 2017; 23(3):e170-e179.","DOI":"10.1111\/hae.13215"},{"key":"78693","doi-asserted-by":"crossref","unstructured":"Raut S, Daniels S, Heath AB, SSC Sub-Committee on Factor. Value assignment of the WHO 8th International Standard for factor VIII, concentrate (07\/350). J Thromb Haemost. 2012; 10(6):1175-1176.","DOI":"10.1111\/j.1538-7836.2012.04714.x"},{"key":"78694","doi-asserted-by":"crossref","unstructured":"Hubbard AR, Hamill M, Beeharry M, Bevan SA, Heath AB, SSC Sub-Committees on Factor VIII\/Factor IX and von Willebrand factor of ISTH. Value assignment of the WHO 6th International Standard for blood coagulation factor VIII and von Willebrand factor in plasma (07\/316). J Thromb Haemost. 2011; 9(10):2100-2102.","DOI":"10.1111\/j.1538-7836.2011.04471.x"},{"key":"78695","doi-asserted-by":"crossref","unstructured":"Bukkems LH, Valke L, Barteling W. Combining factor VIII levels and thrombin\/plasmin generation: a population pharmacokinetic-pharmacodynamic model for patients with haemophilia A. Br J Clin Pharmacol. 2022; 88(6):2757-2768.","DOI":"10.1111\/bcp.15185"},{"key":"78696","doi-asserted-by":"crossref","unstructured":"Maseide RJ, Berntorp E, Nummi V, Lassila R, Tjonnfjord GE, Holme PA. Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation. Haemophilia. 2021; 27(5):793-801.","DOI":"10.1111\/hae.14355"},{"key":"78697","doi-asserted-by":"crossref","unstructured":"Milos M, Coen Herak D, Mahmoud Hourani Soutari N. Overall hemostasis potential and aPTT-clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype. Int J Lab Hematol. 2021; 43(2):273-280.","DOI":"10.1111\/ijlh.13347"},{"key":"78698","doi-asserted-by":"crossref","unstructured":"Dargaud Y, Wolberg AS, Gray E. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2017; 15(8):1704-1707.","DOI":"10.1111\/jth.13743"},{"key":"78699","doi-asserted-by":"crossref","unstructured":"Waters EK, Sigh J, Friedrich U, Hilden I, Sorensen BB. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia. 2017; 23(5):769-776.","DOI":"10.1111\/hae.13260"},{"key":"78700","doi-asserted-by":"crossref","unstructured":"Patel-Hett S, Martin EJ, Mohammed BM. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019; 25(5):797-806.","DOI":"10.1111\/hae.13820"},{"key":"78701","doi-asserted-by":"crossref","unstructured":"Verhagen MJA, Valke L, Schols SEM. Thrombin generation for monitoring hemostatic therapy in hemophilia A: a narrative review. J Thromb Haemost. 2022; 20(4):794-805.","DOI":"10.1111\/jth.15640"},{"key":"78702","doi-asserted-by":"crossref","unstructured":"Adamkewicz JI, Chen DC, Paz-Priel I. Effects and Interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019; 119(7):1084-1093.","DOI":"10.1055\/s-0039-1688687"},{"key":"78703","doi-asserted-by":"crossref","unstructured":"Jenkins PV, Bowyer A, Burgess C. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors\u2019 Organisation guideline. Haemophilia. 2020; 26(1):151-155.","DOI":"10.1111\/hae.13903"},{"key":"78704","doi-asserted-by":"crossref","unstructured":"Shimizu K, Nakajima Y, Takami E, Nakano H, Nogami K. Additional factor X enhances emicizumab-driven coagulation function in patients with hemophilia A and hemophilia A mice. Thromb Haemost. 2025; 125(1):21-32.","DOI":"10.1055\/a-2315-8199"},{"key":"78705","doi-asserted-by":"crossref","unstructured":"Ostergaard H, Lund J, Greisen PJ. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021; 138(14):1258-1268.","DOI":"10.1182\/blood.2020010331"},{"key":"78706","doi-asserted-by":"crossref","unstructured":"Janbain M, Enjolras N, Bolbos R, Brevet M, Bordet JC, Dargaud Y. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: a preclinical study. Haemophilia. 2021; 27(6):1002-1006.","DOI":"10.1111\/hae.14435"},{"key":"78707","doi-asserted-by":"crossref","unstructured":"Sefiane T, Maynadie H, Ettingshausen CE. Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc. Haematologica. 2024; 109(6):1836-1848.","DOI":"10.3324\/haematol.2023.284142"},{"key":"78708","doi-asserted-by":"crossref","unstructured":"Maroney SA, Ferrel JP, Collins ML, Mast AE. Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans. J Thromb Haemost. 2008; 6(8):1344-1351.","DOI":"10.1111\/j.1538-7836.2008.03033.x"},{"key":"78709","doi-asserted-by":"crossref","unstructured":"Muto A, Yoshihashi K, Takeda M. Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014; 12(2):206-213.","DOI":"10.1111\/jth.12474"},{"key":"78710","doi-asserted-by":"crossref","unstructured":"Muto A, Yoshihashi K, Takeda M. Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014; 124(20):3165-3171.","DOI":"10.1182\/blood-2014-07-585737"},{"key":"78711","doi-asserted-by":"crossref","unstructured":"Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol. 2000; 20(5):1362-1373.","DOI":"10.1161\/01.ATV.20.5.1362"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12008\/78270","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12008\/78735","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12008\/78270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:31Z","timestamp":1794046111000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286982","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,3]]}}}